<?xml version='1.0' encoding='utf-8'?>
<document id="28906404"><sentence text="Ticagrelor-induced life-threatening bleeding via the cyclosporine-mediated drug interaction: A case report."><entity charOffset="53-65" id="DDI-PubMed.28906404.s1.e0" text="cyclosporine" /></sentence><sentence text="Ticagrelor has become one of the first-line antiplatelet agents in acute coronary syndrome (ACS) patients recommend by the guideline due to its more potent and predictable antiplatelet effect"><entity charOffset="0-10" id="DDI-PubMed.28906404.s2.e0" text="Ticagrelor" /></sentence><sentence text=" However, bleeding is still a severe drug adverse reaction of ticagrelor therapy" /><sentence text=" We report a first case on ticagrelor-induced life-threatening bleeding via the cyclosporine-mediated drug interaction"><entity charOffset="80-92" id="DDI-PubMed.28906404.s4.e0" text="cyclosporine" /></sentence><sentence text="" /><sentence text="A 58-year-old Chinese male who received cyclosporine 200â€Šmg daily 5 years after renal transplantation"><entity charOffset="40-52" id="DDI-PubMed.28906404.s6.e0" text="cyclosporine" /></sentence><sentence text=" Ticagrelor was added for treating ACS"><entity charOffset="1-11" id="DDI-PubMed.28906404.s7.e0" text="Ticagrelor" /></sentence><sentence text=" Unfortunately, gum bleeding and life-threatening bloody stool appeared 8 days later, accompanied with the sudden drop of blood pressure" /><sentence text="" /><sentence text="Ticagrelor was replaced with clopidogrel"><entity charOffset="0-10" id="DDI-PubMed.28906404.s10.e0" text="Ticagrelor" /><entity charOffset="29-40" id="DDI-PubMed.28906404.s10.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.28906404.s10.e0" e2="DDI-PubMed.28906404.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28906404.s10.e0" e2="DDI-PubMed.28906404.s10.e1" /></sentence><sentence text=" Intravenous injection of proton pump inhibitor and agkistrodon snake venom hemocoagulase were used to stop the bleeding" /><sentence text=" Meanwhile, packed red blood cells and plasma were continuously transfused to maintain adequate blood volume" /><sentence text="" /><sentence text="The patient's bloody stool was well controlled after treatment" /><sentence text="" /><sentence text="The present case demonstrates that a potential drug-drug interaction (DDI) may lead to a life-threatening drug adverse reaction especially in special subjects" /><sentence text=" Therefore, regarding DDI, optimizing antiplatelet treatment should be considered for the efficacy and safety of P2Y12 receptor antagonist in this fragile population" /><sentence text="" /></document>